ESMO Open review: Shadows under the halo of "magic medicine
Time of Update: 2022-09-06
This pooled analysis includes data from before and after the publication of the updated guideline and provides an overview of the current diagnosis and management of ILD/pneumonitis in the T-DXd trial .
The high-level turnover of pharmaceutical companies is frequent, and changes under the medical reform may continue
Time of Update: 2022-09-06
[Pharmaceutical Network Industry News] Recently, AstraZeneca announced that it has appointed Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca.
Aerospace Environmental Engineering Technology Research Institute settled in Taizhou, Zhejiang
Time of Update: 2022-08-19
Wu Huading, secretary of the Linhai Municipal Party Committee, said that the joint construction of the Aerospace Environmental Protection Engineering Technology Research Institute will surely inject a strong impetus into the high-quality development of Linhai's medical and chemical industry .
Scientists have developed a new method to convert cotton recycling into materials such as spandex, nylon and more
Time of Update: 2022-08-17
"Some fabrics still have fibers so strong that they can be reused "Considering that cotton is a renewable resource, this is not particularly energy-efficient," says Edvin Ruuth, a researcher in chemical engineering at Lund University.
Causes of multidrug resistance in tumor therapy
Time of Update: 2022-08-15
Original title:Oxidative stress-mediated up-regulation of ABC transporters in lung cancer cells Researchers from the Suzhou Institute of Biomedical Engineering Technology (SIBEBT) of the Chinese Academy of Sciences have revealed the reasons for the inevitable occurrence of multidrug resistance in the process of tumor treatment through long-term research on the mechanism of tumor multidrug resistance .
The cornerstone of nano-drug delivery-the role of EPR effect in human tumors
Time of Update: 2022-06-26
In view of this, researchers such as Wenguang Liu of Tianjin University have developed an in vitro perfusion model to study the role of EPR in human kidney tumors in real time through X-ray computed tomography (CT) .
Express reduces the risk of death in patients with biliary tract cancer by 20%, and the blockbuster PD-L1 inhibitor combination has been granted priority review by the FDA
Time of Update: 2022-05-27
” Reference:  Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial.
LENZ Therapeutics and Keixing Pharmaceutical reach an exclusive license agreement in Greater China
Time of Update: 2022-05-21
On April 14, LENZ Therapeutics announced that it has signed an exclusive agreement with Keixing Pharma to develop and commercialize LNZ100 (acetylcridine) and LNZ101 (acetylcridine + brimonidine) for the treatment of presbyopia in Greater China.
License Agreement .
Nature Genetics: Why don't most smokers get lung cancer
Time of Update: 2022-05-18
Nature Genetics Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smokingUsing single-cell sequencing technology, the study found that some of the most smokers may have powerful "self-protection mechanisms" that limit the DNA mutations caused by smoking to protect themselves from lung cancer .
This pharmaceutical company has another new ADC drug for clinical application
Time of Update: 2022-05-16
Specifically, BAT8009, which was also approved for clinical use in April, is a B7H3-targeting antibody-drug conjugate (ADC) developed by Bio-Tech, which is intended to be developed for the treatment of solid tumors .
JGH: Efficacy analysis of colon stent placement in the treatment of obstructive colorectal cancer
Time of Update: 2022-05-10
This study demonstrates that SEMS placement in patients undergoing OCC may reduce mortality and length of stay in the short term .
Positive Phase 3 clinical data of Zai Lab's niraparib in first-line maintenance treatment of ovarian cancer patients in China
Time of Update: 2022-04-25
Data from this phase 3 clinical trial showed that maintenance therapy with niraparib had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, regardless of biomarker status; the PRIME study achieved The primary study endpoint, the median PFS of patients in the niraparib group was 24.
Shanghai Jiaotong University Li Can and Cui Daxiang's research group has made new progress in the field of nano-drug delivery carriers
Time of Update: 2022-04-22
Li Can's research group from Bio-X Institute of Shanghai Jiaotong University and Cui Daxiang's research group from School of Electronic Information and Electrical Engineering cooperated to publish a cover article in the internationally renowned academic journal Nanoscale, "Engineered mesenchymal stem cell-derived exosomes with high CXCR4 levels for targeted siRNA gene therapy against cancer", and was included in the "2022 Nanoscale HOT Article Collection" series .
BeiGene Announces New Indication for Zanubrutinib: First-Line Treatment of Waldenström's Macroglobulinemia
Time of Update: 2022-03-09
Complete remission (CR) and very good partial response in the overall intention-to-treat population in the Baiyueze® treatment group as assessed by an independent review committee according to the 6th International Symposium on Waldenström's Macroglobulinemia Revised Response Criteria (Treon2015) The response (VGPR) rate was 28% (95% CI: 20, 38) compared with 19% (95% CI: 12, 28) in the ibrutinib arm .
Nat Cell Biol Zhu Xiaofan/Gu Jin/Cheng Tao team collaboration revealed the essence of leukemia minimal residual disease for the first time
Time of Update: 2022-03-08
By comparing the single-cell transcriptome data of leukemia cells in three stages of initial diagnosis, D19 and relapse, the authors found that the differentiation stage of residual leukemia cells has no significant characteristics, but the cell cycle is more in a quiescent state, and the hypoxia signaling pathway is significantly activated .